US

Ribon Therapeutics lands $65 mln Series B

Lexington, Massachusetts-based Ribon Therapeutics, a biotechnology company, has raised $65 million in Series B financing. Novartis Venture Fund led the round with participation from JJDC, Celgene Corporation, The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital.

Swiss health tech company Sophia Genetics picks up $77 mln

Sophia Genetics, a Swiss health tech company, has raised $77 million in funding. Generation Investment Management led the round with participation from other investors that included Idinvest Partners, Balderton Capital and Alychlo.

Oculis nets about $15.6 mln

Oculis, a Swiss developer of ophthalmic drugs, has raised CHF 15.5 million (about $15.6 million) in funding. Tekla Capital Management LLC led the round with participation from other investors that included Nan Fung Life Sciences.

Cell therapy company Immusoft inks $20 mln Series B

Seattle-based Immusoft Corporation, a cell therapy company, has raised $20 million in Series B financing. The investors included Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners and Mesa Verde Venture Partners.

March Capital raises $302 mln for venture, opportunity funds

March Capital Partners has raised a $156.6 million second venture-capital fund and a $145.4 million second opportunity fund, according to a pair of filings with the SEC.

Mary Meeker swings for more than $1 bln for Bond

Revered venture capitalist Mary Meeker is seeking to raise $1.25 billion on a hard cap of $1.5 billion for a debut fund for her new venture capital firm, Bond, according to a report from Axios.

Ostara picks up $11 mln

Vancouver, British Columbia-based Ostara, a provider of nutrient management solutions to farms, municipalities and industries, has raised $11 million in funding. Wheatsheaf Group Limited and VantagePoint Capital Partners led the round. The capital will be used to scale the company's fertilizer production as well as support its expansion.

Triventures ARC targets $45 mln for healthcare seed fund

Triventures ARC, a venture capital arm of the ARC Innovation Center at Sheba Medical Center, an Israeli hospital, is seeking to raise $45 million for a fund focused on seed investments in healthcare innovations. Triventures, which is based in Herzliya, Israel and Menlo Park, California, will manage Triventures ARC.

Ablative Solutions takes in $77 mln Series D

Kalamazoo, Michigan and San Jose, California-based Ablative Solutions Inc, a company focused on treating hypertension, has secured $77 million in Series D funding. Gilde Healthcare and BioStar Ventures led the round with participation from other investors that included Michigan Accelerator Fund and Novus Biotechnology.

Tiburio Therapeutics grabs $31 mln Series A

Cambridge, Massachusetts-based Tiburio Therapeutics, a biopharmaceutical company newly launched by Cydan, has raised $31 million in Series A funding. The investors were New Enterprise Associates, Longitude Capital, Lundbeckfonden Ventures and Alexandria Venture Investments.